Susquehanna International Group, LLP Vir Biotechnology, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$7.26 - $10.7 $272,976 - $402,320	-37,600 Reduced 33.97%	73,100 $547,000
Q2 2024 Aug 15, 2024	SELL	$7.63 - $12.66 $192,276 - $319,032	-25,200 Reduced 18.54%	110,700 $985,000
Q1 2024 May 07, 2024	BUY	$8.6 - $11.9 $843,660 - $1.17 Million	98,100 Added 259.52%	135,900 $1.38 Million
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $76,824 - $101,870	9,900 Added 35.48%	37,800 $380,000
Q3 2023 Nov 14, 2023	SELL	$9.14 - $24.62 $2.25 Million - $6.07 Million	-246,400 Reduced 89.83%	27,900 $261,000
Q2 2023 Aug 11, 2023	BUY	$23.2 - $27.29 $3.85 Million - $4.53 Million	166,000 Added 153.28%	274,300 $6.73 Million
Q1 2023 May 16, 2023	BUY	$22.26 - $30.85 $1.56 Million - $2.17 Million	70,300 Added 185.0%	108,300 $2.52 Million
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $1.43 Million - $2.02 Million	-71,500 Reduced 65.3%	38,000 $961,000
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $387,112 - $659,320	-21,200 Reduced 16.22%	109,500 $2.11 Million

220

87.4M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.06B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.